Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So much for our CEO being honest. BS POS company.
7 days left in quarter. Are we still waiting for data?
Ugly one day chart. No volume. Dropped like a rock. More of the same.
Could be more of the same . Big build up for disappointment.
Without partnership we won't see $6.
I hope your'e being facetious. AKA?
More fluff. Mini rally fades away.
Looks like someone wants out . How many more millions are they holding?
Less than 1% ownership. Stock has been under $5 mostly YTD. Wouldn't expect a change.
Hold at best. Shorts have upper hand right now.
Still a penny stock only worse were listed on the NASDAQ.
Uplisting a mistake. Institutional ownership is paltry, < $5.00 dead money is correct.
I think lawsuits are noise. We have much more concerns with this CO.
Data won't come soon enough . Back to 3.30 or below. I think they will stall until end of March.
More blah, blah, blah, and not delivering.
I see how much this great news is affecting the PPS in anticipation of the MS conference today.
You must be a daytrader, I am not.
Another head fake. Can't sustain with no news. Company focus on broadbased CNS diseases.
32 patient clinical trial going on forever with no results.
Usual slide back below $4.
One step forward, two steps backward. The PPS reflects it.
Another useless PR. Where is the focus for alz?
Shorts still have upperhand.
Death Spiral
Better hold $3.30 or will see 2's quick.
I have not seen any indication of them applying for a federal grant from the Department of Health and Human Services, have you?
While a 70% improvement on 32 patients is good, a 70% improvement on 1000 patients would be conviction. IMO.
Why does stock continue lower after previous data? Trial is too small, IMO.
If we go below $3.30 this week we could be in trouble. $.88 pre- split terrible.
I agree. Sell on data news. Stock has lost its momentum. Will have a hard time finding partner with only 32 patients no matter what the data says. Buyout is slim possibility. IMO.
Pre-split $1.72 not very impressive.
INTL does it look like another wave before EOD?
$1.78 pre-
split! Whew Whew!
Will this stock be at $1 in ten yrs?
Since PartB has been extended to 52 weeks when will it end? March 2016? When would Phase3 start? June 2016?
Anavex could become over the counter med (like aspirin) if it keeps it safety record intact.$$$$
You are correct DR. He's a sandbagger.
He knows more than he's saying. The SEC would be all over him if he said positive or negative things about a recently uplisted stock with a low float. JMO.
I am sure he has hundreds of tweets he can comment on. Says he looked at this around 3 weeks ago. Sandbagger.
Interesting he chose to comment on a stock he claims to know nothing about.
Coming up next.
See if you can catch the viewers name asking his opinion. Caught me off guard yesterday. I beleive it's right after his opinion on BWLD.